Because NME1 transcript levels were decreased in colon cancer cells upon Lovastatin treatment (Table 3), it is tempting to speculate that acting on this complex might permit counteracting other members of the cholesterol metabolism pathway that act downstream of NME1, together with key cancer nodes identified by topology network analysis (MYC, CCND1, BCL2...) linked to NME1. Here, BCL2 is linked to malignant colon neoplasm.